Trials / Completed
CompletedNCT04862338
Pharmacodynamics and Tolerance of Nicotinamide Mononucleotide (NMN, 400mg/Day) in Healthy Adults
Pharmacodynamics and Tolerance Study of Nicotinamide Mononucleotide (NMN) Supplementation at 400 mg/Day
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 17 (actual)
- Sponsor
- Seneque SA · Industry
- Sex
- All
- Age
- 30 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to evaluate the physiological and/or biological actions of nicotinamide mononucleotide (NMN-C) in healthy adults receiving a repeated-dose over the course of 28 days by studying the tolerance and pharmacodynamics of this product.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DIETARY_SUPPLEMENT | Nicotinamide mononucleotide (NMN-C) | Nicotinamide mononucleotide (NMN-C) at 400 mg/day for 28 days in total |
Timeline
- Start date
- 2021-04-26
- Primary completion
- 2021-09-08
- Completion
- 2022-04-04
- First posted
- 2021-04-28
- Last updated
- 2023-01-26
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT04862338. Inclusion in this directory is not an endorsement.